Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Global Payments Inc (GPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Global Payments Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Global Payments Inc trades at $76.09 (market cap $20.80B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Global Payments Inc pays a 1.32% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GPN | |
|---|---|---|
Market Cap | $39.89B | $20.80B |
Sector | Health | Industrials |
52-Week High | $491.22 | $90.01 |
52-Week Low | $278.09 | $62.47 |
Enterprise Value | $38.15B | $38.52B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Global Payments (GPN) trades at $76.04, up 2.23% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company maintains solid operating cash flow of $2.66B for 2025 and a gross profit margin of 67.34%, though net income margin turned negative at -7.97% for 2026. Recent developments include AI-powered POS launches and expansion of restaurant partnerships, driving positive analyst sentiment with a consensus price target of $81.56.
GPN presents a mixed outlook: upside exists from earnings momentum and strategic initiatives like the Worldpay integration, but risks include margin pressure, rising debt-to-asset ratio of 41.57%, and intense fintech competition. The stock's current valuation at a P/E of 27.96 appears reasonable relative to growth prospects, yet investors must weigh execution risks against potential rewards in a competitive payments landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
